Atsushi Shiozaki1, Michihiro Kudou2, Daisuke Ichikawa2, Hitoshi Fujiwara2, Hiroki Shimizu2, Takeshi Ishimoto2, Tomohiro Arita2, Toshiyuki Kosuga2, Hirotaka Konishi2, Shuhei Komatsu2, Kazuma Okamoto2, Yoshinori Marunaka3,4, Eigo Otsuji2. 1. Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. shiozaki@koto.kpu-m.ac.jp. 2. Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. 3. Department of Molecular Cell Physiology and Bio-Ionomics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan. 4. Japan Institute for Food Education and Health, St. Agnes' University, Kyoto, 602-8013, Japan.
Abstract
BACKGROUND: Recent evidence suggests that the targeting of membrane proteins specifically activated in cancer stem cells (CSCs) is an important strategy for cancer therapy. The objectives of the present study were to investigate the expression and activity of ion-transport-related molecules in the CSCs of esophageal squamous cell carcinoma. METHODS: Cells exhibiting strong aldehyde dehydrogenase 1 family member A1 (ALDH1A1) activity were isolated from TE8 cells by fluorescence-activated cell sorting, and CSCs were then generated with the sphere formation assay. The gene expression profiles of CSCs were examined by microarray analysis. RESULTS: Among TE8 cells, ALDH1A1 messenger RNA and protein levels were higher in CSCs than in non-CSCs. The CSCs obtained were resistant to cisplatin and had the ability to redifferentiate. The results of the microarray analysis revealed that the expression of 50 genes encoding plasma membrane proteins was altered in CSCs, whereas that of several genes related to ion channels, including transient receptor potential vanilloid 2 (TRPV2), was upregulated. The TRPV2 inhibitor tranilast was more cytotoxic at a lower concentration in CSCs than in non-CSCs, and effectively decreased the number of tumorspheres. Furthermore, tranilast significantly decreased the cell population that strongly expressed ALDH1A1 among TE8 cells. CONCLUSIONS: The results of the present study suggest that TRPV2 is involved in the maintenance of CSCs, and that its specific inhibitor, tranilast, has potential as a targeted therapeutic agent against esophageal squamous cell carcinoma.
BACKGROUND: Recent evidence suggests that the targeting of membrane proteins specifically activated in cancer stem cells (CSCs) is an important strategy for cancer therapy. The objectives of the present study were to investigate the expression and activity of ion-transport-related molecules in the CSCs of esophageal squamous cell carcinoma. METHODS: Cells exhibiting strong aldehyde dehydrogenase 1 family member A1 (ALDH1A1) activity were isolated from TE8 cells by fluorescence-activated cell sorting, and CSCs were then generated with the sphere formation assay. The gene expression profiles of CSCs were examined by microarray analysis. RESULTS: Among TE8 cells, ALDH1A1 messenger RNA and protein levels were higher in CSCs than in non-CSCs. The CSCs obtained were resistant to cisplatin and had the ability to redifferentiate. The results of the microarray analysis revealed that the expression of 50 genes encoding plasma membrane proteins was altered in CSCs, whereas that of several genes related to ion channels, including transient receptor potential vanilloid 2 (TRPV2), was upregulated. The TRPV2 inhibitor tranilast was more cytotoxic at a lower concentration in CSCs than in non-CSCs, and effectively decreased the number of tumorspheres. Furthermore, tranilast significantly decreased the cell population that strongly expressed ALDH1A1 among TE8 cells. CONCLUSIONS: The results of the present study suggest that TRPV2 is involved in the maintenance of CSCs, and that its specific inhibitor, tranilast, has potential as a targeted therapeutic agent against esophageal squamous cell carcinoma.
Entities:
Keywords:
Cancer stem cell; Esophageal squamous cell carcinoma; TRPV2; Tranilast
Authors: Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl Journal: Cancer Res Date: 2006-09-21 Impact factor: 12.701
Authors: Sara Darakhshan; Ali Bidmeshkipour; Kamran Mansouri; Hakhamaneshi Mohammad Saeid; Ali Ghanbari Journal: Iran J Pharm Res Date: 2014 Impact factor: 1.696
Authors: Kodappully S Siveen; Parveen B Nizamuddin; Shahab Uddin; Mohamed Al-Thani; Michael Paul Frenneaux; Ibrahim A Janahi; Martin Steinhoff; Fouad Azizi Journal: Dis Markers Date: 2020-12-10 Impact factor: 3.434
Authors: Jared Anthony Crasto; Mitchell Stephen Fourman; Alejandro Morales-Restrepo; Adel Mahjoub; Jonathan Brendan Mandell; Kavita Ramnath; Jessica C Tebbets; Rebecca J Watters; Kurt Richard Weiss Journal: Oncotarget Date: 2018-07-10